M&A Deal Summary

Biocare Medical Acquires Empire Genomics

On November 22, 2022, Biocare Medical acquired medical products company Empire Genomics

Acquisition Highlights
  • This is Biocare Medical’s 1st transaction in the Medical Products sector.
  • This is Biocare Medical’s 1st transaction in the United States.
  • This is Biocare Medical’s 1st transaction in New York.

M&A Deal Summary
Date 2022-11-22
Target Empire Genomics
Sector Medical Products
Buyer(s) Biocare Medical
Deal Type Add-on Acquisition

Target

Empire Genomics

Williamsville, New York, United States
Empire Genomics provides the clinical, research, and drug discovery community with the tools they need to advance scientific discovery. Empire Genomics product portfolio includes Fluorescence in situ Hybridization (FISH) and Chromogenic in situ Hybridization (CISH) probes designed and optimized for specific diseases, genes, or regions across the entire human and mouse genomes. Empire Genomics was founded in 2006 and is based in Williamsville, New York.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Biocare Medical

Pacheco, California, United States
Category Company
Founded 1997
Sector Test/Measurement Equipment
DESCRIPTION

Biocare Medical is a provider of immunohistochemistry (IHC) instrumentation, as well as a full range of reagents for IHC and molecular testing. The company engages in IHC and molecular diagnostic reagents, including simultaneous Multiplex IHC tests that provide increased confidence at critical diagnostic decision points, positively influencing patient therapy while accelerating turnaround time. Biocare Medical was founded in 1997 and is based in Pacheco, California.

DEAL STATS #
Overall 1 of 1
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Mergr

Product

Company

Legal